EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,711 | -96.7% | 88 | -95.1% | 0.00% | -100.0% |
| Q1 2023 | $51,407 | +106.4% | 1,812 | +112.7% | 0.01% | +66.7% |
| Q4 2022 | $24,904 | +55.6% | 852 | +41.5% | 0.00% | +50.0% |
| Q3 2022 | $16,000 | +433.3% | 602 | +937.9% | 0.00% | – |
| Q2 2022 | $3,000 | -50.0% | 58 | -54.0% | 0.00% | -100.0% |
| Q1 2022 | $6,000 | +200.0% | 126 | +162.5% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 48 | +9.1% | 0.00% | – |
| Q3 2021 | $2,000 | +100.0% | 44 | +144.4% | 0.00% | – |
| Q2 2021 | $1,000 | -50.0% | 18 | -50.0% | 0.00% | – |
| Q1 2021 | $2,000 | +100.0% | 36 | +80.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 20 | +25.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 16 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 16 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | – | 16 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |